Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;30(7):2500074.
doi: 10.2807/1560-7917.ES.2025.30.7.2500074.

Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025

François Blanquart  1 , Vincent Vieillefond  2 , Benoit Visseaux  3 , Claire Nour Abou Chakra  4 , Marta C Nunes  4   5 , Alexandra Jacques  6 , Stephanie Haim-Boukobza  7 , Laurence Josset  8   9 , Valentin Wehrle  10 , Guillaume Deleglise  11 , Thomas Duret  11 , Marie Anne Rameix-Welti  12   13 , Bruno Lina  8   9 , Vincent Enouf  13 ; RELAB study group  14 ; Antonin Bal  8   9
Affiliations

Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025

François Blanquart et al. Euro Surveill. 2025 Feb.

Abstract

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).

Keywords: acute respiratory infection; influenza; surveillance; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
(A) Influenza test positivity per week, for non-vaccinated individuals and individuals vaccinated this season (15 days–3 months prior), (B, C, D) influenza positivity stratified by age group, France, October 2024–February 2025 (n = 59,472)
Figure 2
Figure 2
Vaccine effectiveness against influenza overall, and stratified by virus type and/or characteristics of individuals in the study, as well as overall vaccine effectiveness in a subset of participants tested with a single kind of PCR assaya, France, October 2024–February 2025 (n = 59,472)
See this image and copyright information in PMC

References

    1. Robert Koch Instute (RKI). RKI – Aktueller Wochenbericht – GrippeWeb-Wochenbericht. [Current weekly report – GrippeWeb weekly report]. Berlin: RKI. [Accessed 24 Jan 2025]. Available from: https://www.rki.de/DE/Content/Infekt/Sentinel/Grippeweb/Wochenberichte/W...
    1. RespiVirNet – Sorveglianza integrata dei virus respiratori. Rapporto influnet. [Integrated Surveillance of Respiratory Viruses. Influenza Report]. Rome: Istituto Superiore di Sanità. [Accessed 24 Jan 2025]. Available from: https://respivirnet.iss.it/pagine/rapportoInflunet.aspx
    1. Santé publique France (SPF). Infections respiratoires aiguës (grippe, bronchiolite, COVID-19). [Acute respiratory infections (influenza, bronchiolitis, COVID-19)]. Bulletin du 8 janvier 2025. Saint Maurice: SPF. [Accessed 21 Jan 2025]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-...
    1. UK Health Security Agency (UKHSA). Influenza | UKHSA data dashboard. London: UKHSA. [Accessed 24 Jan 2025]. Available from: https://ukhsa-dashboard.data.gov.uk/respiratory-viruses/influenza
    1. European Respiratory Virus Surveillance Summary (ERVISS). [Accessed 24 Jan 2025]. Available from: https://erviss.org/

MeSH terms

Substances

LinkOut - more resources